Etripamil (Synonyms: MSP-2017; (-)-MSP-2017) |
Catalog No.GC65248 |
Etripamil (MSP-2017) es un antagonista de los canales de calcio de tipo L de acciÓn corta que se puede utilizar para la investigaciÓn de la taquicardia supraventricular paroxÍstica (PSVT).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1593673-23-4
Sample solution is provided at 25 µL, 10mM.
Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2].
[1]. Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497.
[2]. Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *